Peptide clinical trials in progress
- By Reed Calder
- Last reviewed Nov 16, 2026
- Every record opened by hand
The short answer
On November 13, 2026, ClinicalTrials.gov listed 24 trials of the compounds on this site that are active but no longer recruiting, and 33 more that finished since January 2025 with no results posted. Since then we added 3 active trials (oxytocin 2, triptorelin 1) and 16 finished trials (kisspeptin 1, NAD+ 2, glutathione 5, oxytocin 7, triptorelin 1), so the page now lists 27 and 49. Retatrutide has 9 active and 9 finished trials, all Eli Lilly’s. Cagrilintide and CagriSema have 7 and 18, all Novo Nordisk’s. TRIUMPH-Outcomes, 10,000 people, is due to finish in February 2029. Semaglutide has 51 active trials and tirzepatide 31, which we link rather than list.
A trial that has stopped recruiting is not finished. People are still being treated and followed, and the results come later. This page lists those trials, and the ones that have finished but show no results on the registry, so you can see what is still to be reported. You can’t join these. Trials that are open to new participants are on the recruiting page. We opened every record ourselves and kept the ones that name the compound as a treatment.
How to read the list
- Active, not recruiting: the study is continuing, with participants receiving a treatment or being examined, but new participants are not being recruited or enrolled.
- Completed: the study has ended normally and the last participant’s last visit has happened.
- Primary completion: when the last person is examined or treated for the main result. The registry says the study’s responsible party must update it once it is reached.
Sources for these definitions: ClinicalTrials.gov. A trial that is running or finished hasn’t shown a compound is safe or effective, and an empty results page doesn’t mean no results exist (Health Canada, 2026).
Active, not recruiting
27 trials, grouped by compound. Registry data as of Nov 13, 2026. Sponsor names are as the registry spells them.
Retatrutide
All nine are Eli Lilly’s. They are fully enrolled and still treating or following people. TRIUMPH-Outcomes, the largest, has an estimated primary completion date of February 2029. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06260722 | TRANSCEND-T2D-2: Retatrutide against semaglutide in adults with type 2 diabetes whose blood sugar isn’t controlled on metformin, with or without an SGLT2 inhibitor. | Phase 3, 1,250 people. Randomized, open label. | Eli Lilly and Company. 77 sites in 5 countries and regions. Active, not recruiting. Started Feb 2024; primary completion Aug 2026 (date has passed). Record updated Sep 2026. |
| NCT06859268 | TRIUMPH-6: Retatrutide or placebo for keeping weight off after weight loss, in people with obesity. | Phase 3, 643 people. Randomized, placebo, blinded. | Eli Lilly and Company. 53 sites in Canada, United Kingdom, United States. Active, not recruiting. Started Mar 2025; primary completion Apr 2028 (est.). Record updated Mar 2026. |
| NCT06297603 | TRANSCEND-T2D-3: Retatrutide or placebo in adults with type 2 diabetes and moderate or severe kidney impairment, on basal insulin. | Phase 3, 320 people. Randomized, placebo, blinded. | Eli Lilly and Company. 76 sites in 7 countries and regions. Active, not recruiting. Started Mar 2024; primary completion Oct 2026 (date has passed). Record updated Nov 2026. |
| NCT07035093 | TRIUMPH-7: Retatrutide or placebo in adults with obesity or overweight and chronic low back pain. | Phase 3, 586 people. Randomized, placebo, blinded. | Eli Lilly and Company. 40 sites in 4 countries and regions. Active, not recruiting. Started May 2025; primary completion Sep 2027 (est.). Record updated Sep 2026. |
| NCT07232719 | TRIUMPH-8: Retatrutide or placebo in adults with obesity or overweight. | Phase 3, 250 people. Randomized, placebo, blinded. | Eli Lilly and Company. 31 sites in United Kingdom, United States. Active, not recruiting. Started Nov 2025; primary completion Jun 2027 (est.). Record updated Nov 2026. |
| NCT07357415 | TRIUMPH-9: Retatrutide in adults without type 2 diabetes who have obesity or overweight, blinded. | Phase 3, 600 people. Randomized, blinded. | Eli Lilly and Company. 35 sites in Argentina, Canada, United States. Active, not recruiting. Started Jan 2026; primary completion Oct 2028 (est.). Record updated Jun 2026. |
| NCT06383390 | TRIUMPH-Outcomes: Retatrutide or placebo for heart and kidney outcomes in adults with obesity and atherosclerotic cardiovascular disease. | Phase 3, 10,000 people. Randomized, placebo, blinded. | Eli Lilly and Company. 742 sites in 27 countries and regions. Active, not recruiting. Started Apr 2024; primary completion Feb 2029 (est.). Record updated Oct 2026. |
| NCT06662383 | TRIUMPH-5: Retatrutide against tirzepatide in adults with obesity. | Phase 3, 800 people. Randomized, blinded. | Eli Lilly and Company. 65 sites in 5 countries and regions. Active, not recruiting. Started Nov 2024; primary completion Nov 2026 (est.). Record updated Jul 2026. |
| NCT06982859 | How retatrutide, semaglutide or placebo change insulin secretion and insulin sensitivity in adults with type 2 diabetes. | Phase 1, 95 people. Randomized, placebo, blinded. | Eli Lilly and Company. 1 site, Germany. Active, not recruiting. Started Jun 2025; primary completion Jan 2027 (est.). Record updated Oct 2026. |
Cagrilintide and CagriSema
All seven are Novo Nordisk’s. REDEFINE 1 reached its primary completion date in October 2024 and is still listed as active, with no results posted on the registry. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06780449 | CagriSema or placebo for long-term weight loss in people with obesity. | Phase 3, 400 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 36 sites in 6 countries and regions. Active, not recruiting. Started Feb 2025; primary completion Aug 2028 (est.). Record updated Jan 2026. |
| NCT07220642 | RENEW 1: Cagrilintide or placebo for weight loss in people with overweight or obesity. | Phase 3, 300 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 40 sites in 10 countries and regions. Active, not recruiting. Started Nov 2025; primary completion May 2027 (est.). Record updated Aug 2026. |
| NCT07184086 | How weight loss on CagriSema changes metabolism compared with weight loss by diet, in people with obesity. | Phase 1, 80 people. Randomized, open label. | Novo Nordisk A/S. 2 sites, United States. Active, not recruiting. Started Sep 2025; primary completion Oct 2027 (est.). Record updated Sep 2026. |
| NCT07011667 | CagriSema or placebo for losing weight and keeping it off in people with obesity. | Phase 3, 609 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 47 sites, United States. Active, not recruiting. Started Jun 2025; primary completion Mar 2027 (est.). Record updated Sep 2026. |
| NCT05669755 | REDEFINE 3: CagriSema or placebo for heart attacks and strokes in people with cardiovascular disease. | Phase 3, 7,101 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 633 sites in 25 countries and regions. Active, not recruiting. Started Mar 2023; primary completion Sep 2027 (est.). Record updated Aug 2026. |
| NCT07220759 | RENEW 2: Cagrilintide or placebo for weight loss in people with overweight or obesity and type 2 diabetes. | Phase 3, 330 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 67 sites in 11 countries and regions. Active, not recruiting. Started Nov 2025; primary completion May 2027 (est.). Record updated Oct 2026. |
| NCT05567796 | REDEFINE 1: CagriSema, cagrilintide, semaglutide or placebo for weight loss in people with excess body weight. | Phase 3, 3,400 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 256 sites in 23 countries and regions. Active, not recruiting. Started Nov 2022; primary completion Oct 2024 (date has passed). Record updated Sep 2026. |
Thymosin alpha-1 (thymalfasin)
Three trials in China, in cancer treatment and in sepsis. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06056804 | Chemoradiotherapy before surgery, with a PD-1 antibody and thymalfasin, for locally advanced rectal cancer. | Phase 2, 20 people. One group, open label. | Beijing Friendship Hospital. 2 sites, China. Active, not recruiting. Started Jan 2024; primary completion Dec 2024 (date has passed). Record updated Apr 2025. |
| NCT07922954 | Standard care plus thymosin alpha-1 in adults with sepsis, to see whether it changes IgM levels. One group, no comparison. | Phase 4, 36 people. One group, open label. | Southeast University, China. 1 site, China. Active, not recruiting. Started Feb 2026; primary completion Jan 2027 (est.). Record updated Nov 2026. |
| NCT06401447 | Chemoradiotherapy with immunotherapy for locally advanced esophageal cancer. Thymosin alpha-1 is one part of the regimen. | No drug phase, 50 people. One group, open label. | Fudan University. 1 site, China. Active, not recruiting. Started Dec 2023; primary completion Jul 2026 (est.) (date has passed). Record updated Apr 2026. |
SS-31 (elamipretide)
Elamipretide is the drug name for SS-31. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06373731 | ReNEW: Elamipretide (SS-31) or placebo, injected under the skin, in dry age-related macular degeneration. | Phase 3, 313 people. Randomized, placebo, blinded. | Stealth BioTherapeutics Inc.. 53 sites in 8 countries and regions. Active, not recruiting. Started May 2024; primary completion Aug 2027 (est.). Record updated Sep 2026. |
MK-677 (ibutamoren) and LUM-201
LUM-201 is the same compound as MK-677. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT04806854 | OraGrowtH212: How the body handles LUM-201 (the same compound as MK-677) and what it does, in children with idiopathic growth hormone deficiency. | Phase 2, 24 people. Randomized, open label. | Lumos Pharma. 1 site, Chile. Active, not recruiting. Started Jul 2021; primary completion Apr 2030 (est.). Record updated Oct 2023. |
PT-141 (bremelanotide)
Bremelanotide is the drug name for PT-141. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06565611 | BMT-801: Bremelanotide (PT-141) together with tirzepatide for obesity. | Phase 2, 108 people. Randomized, blinded. | Palatin Technologies, Inc. 4 sites, United States. Active, not recruiting. Started Aug 2024; primary completion Feb 2025 (date has passed). Record updated Mar 2025. |
Melanotan 1 (afamelanotide)
Afamelanotide is the drug name for Melanotan 1. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06109649 | Afamelanotide, sold as Scenesse, with narrow-band UV light against light alone in vitiligo. | Phase 3, 200 people. Randomized, open label. | Clinuvel, Inc.. 30 sites in 4 countries and regions. Active, not recruiting. Started Oct 2023; primary completion Dec 2025 (est.) (date has passed). Record updated Jul 2025. |
Cerebrolysin
A mixture of small peptides from pig brain. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT05755997 | CERICA: Cerebrolysin or saline placebo in CADASIL, an inherited disease of the small blood vessels in the brain. | Phase 2, 30 people. Randomized, blinded. | Ever Neuro Pharma GmbH. 1 site, Czechia. Active, not recruiting. Started Nov 2023; primary completion Mar 2026 (est.) (date has passed). Record updated Feb 2025. |
Oxytocin
Added Nov 16, 2026. Oxytocin added to psychosocial treatment in schizophrenia in Germany, and a three-site crossover trial in chronic pain in Canada. Oxytocin is also an approved injection for labor and bleeding after birth; those trials are counted, not listed. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06881810 | OXY-APS: Syntocinon nasal spray (80 IU, 20 puffs, twice a week for 12 weeks) or placebo spray, taken 45 to 75 minutes before an individualized social-skills therapy, in schizophrenia spectrum disorders. The main measure is the Personal and Social Performance Scale. | Phase 2, 98 people. Randomized, placebo, blinded. | Central Institute of Mental Health, Mannheim. 1 site, Germany. Active, not recruiting. Started Aug 2024; primary completion Mar 2028 (est.). Record updated Aug 2026. |
| NCT04903002 | Nasal oxytocin at 24 IU or 48 IU, or placebo, each as a 2-week course in sequence, in adults with chronic pain, to see whether it changes pain intensity and pain-related interference. | Phase 2/3, 336 people. Randomized, placebo, blinded. | Memorial University of Newfoundland. 3 sites, Canada. Active, not recruiting. Started Apr 2022; primary completion Mar 2026 (est.) (date has passed). Record updated Feb 2026. |
Triptorelin
Added Nov 16, 2026. Debiopharm’s LIBELULA trial of a 12-month triptorelin injection in children with central precocious puberty. Eleven more active records name triptorelin only as one of several allowed hormone drugs, mostly in prostate cancer radiotherapy and drug trials, and are counted in the large-programs table. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06129539 | Debio 4326, a 12-month triptorelin injection, in children with central precocious puberty (LIBELULA). One group, no comparison; the main measure is LH suppression 52 weeks after the first injection. | Phase 3, 56 people. One group, open label. | Debiopharm International SA. 17 sites in 5 countries and regions. Active, not recruiting. Started Jul 2024; primary completion Oct 2026 (est.) (date has passed). Record updated Oct 2026. |
10 of the 27 rows show a primary completion date that has already passed, yet the record still says active. The registry says the responsible party must update the date once it is reached (ClinicalTrials.gov), so these records may be out of date. We haven’t contacted anyone to check.
Finished, no results posted
49 trials that the registry marks completed, with a primary completion date on or after January 1, 2025 and no results posted. The kisspeptin trial was added on Nov 15, 2026 and the NAD+, glutathione and triptorelin trials on Nov 16, 2026. Results for some have been reported elsewhere, in journals or company announcements, before the registry shows them.
Retatrutide
Eli Lilly’s TRIUMPH-1 to TRIUMPH-4 and TRANSCEND-T2D-1 are here. The registry shows no results for any of the nine. The retatrutide page covers what has been reported elsewhere. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT05929066 | TRIUMPH-1: Retatrutide or placebo in adults with obesity or overweight. | Phase 3, 2,335 people. Randomized, placebo, blinded. | Eli Lilly and Company. 134 sites in 12 countries and regions. Completed. Started Jul 2023; primary completion Apr 2026. No results posted. Record updated Aug 2026. |
| NCT05929079 | TRIUMPH-2: Retatrutide or placebo in adults with type 2 diabetes and obesity or overweight. | Phase 3, 1,152 people. Randomized, placebo, blinded. | Eli Lilly and Company. 98 sites in 8 countries and regions. Completed. Started Jul 2023; primary completion Jun 2026. No results posted. Record updated Jul 2026. |
| NCT05882045 | TRIUMPH-3: Retatrutide or placebo in adults with obesity and cardiovascular disease. | Phase 3, 1,946 people. Randomized, placebo, blinded. | Eli Lilly and Company. 169 sites in 10 countries and regions. Completed. Started May 2023; primary completion Apr 2026. No results posted. Record updated Jul 2026. |
| NCT05931367 | TRIUMPH-4: Retatrutide or placebo in adults with obesity or overweight and knee osteoarthritis. | Phase 3, 445 people. Randomized, placebo, blinded. | Eli Lilly and Company. 49 sites in 6 countries and regions. Completed. Started Aug 2023; primary completion Nov 2025. No results posted. Record updated Jan 2026. |
| NCT06354660 | TRANSCEND-T2D-1: Retatrutide or placebo in adults with type 2 diabetes treated with diet and exercise alone. | Phase 3, 537 people. Randomized, placebo, blinded. | Eli Lilly and Company. 48 sites in 4 countries and regions. Completed. Started Apr 2024; primary completion Jan 2026. No results posted. Record updated Mar 2026. |
| NCT06313528 | How retatrutide changes calorie intake and energy use in adults with obesity, against placebo. | Phase 1, 85 people. Randomized, placebo, blinded. | Eli Lilly and Company. 3 sites, United States. Completed. Started Mar 2024; primary completion Aug 2025. No results posted. Record updated Sep 2025. |
| NCT05916560 | How the body handles retatrutide in people with impaired and normal liver function. | Phase 1, 43 people. Not randomized, open label. | Eli Lilly and Company. 5 sites, United States. Completed. Started Jul 2023; primary completion Mar 2025. No results posted. Record updated Apr 2025. |
| NCT06808802 | Whether retatrutide changes how the body handles metoprolol, in healthy adults. | Phase 1, 30 people. One group, open label. | Eli Lilly and Company. 1 site, Singapore. Completed. Started Feb 2025; primary completion Apr 2025. No results posted. Record updated Jun 2025. |
| NCT06982846 | How people with type 2 diabetes on retatrutide respond to low blood sugar, against placebo. | Phase 1, 80 people. Randomized, placebo, blinded. | Eli Lilly and Company. 1 site, Austria. Completed. Started Jun 2025; primary completion May 2026. No results posted. Record updated Jun 2026. |
Cagrilintide and CagriSema
Eighteen Novo Nordisk trials, including REIMAGINE 1, 2, 3 and 5, REDEFINE 2 and REDEFINE 6. The cagrilintide page covers what has been reported elsewhere. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06388187 | Different doses of CagriSema against placebo for weight loss in people with excess body weight. | Phase 3, 300 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 25 sites in 5 countries and regions. Completed. Started Jun 2024; primary completion Apr 2026. No results posted. Record updated May 2026. |
| NCT06323161 | REIMAGINE 3: CagriSema or placebo for blood sugar and weight in type 2 diabetes treated with once-daily basal insulin, with or without metformin. | Phase 3, 274 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 61 sites in 6 countries and regions. Completed. Started Mar 2024; primary completion Sep 2025. No results posted. Record updated Sep 2026. |
| NCT06403761 | How CagriSema, semaglutide and cagrilintide affect insulin action in people with type 2 diabetes. | Phase 1, 158 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 1 site, Germany. Completed. Started May 2024; primary completion Dec 2025. No results posted. Record updated Feb 2026. |
| NCT06267092 | How CagriSema works on appetite in people with excess body weight, against placebo. | Phase 1, 164 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 1 site, Germany. Completed. Started Feb 2024; primary completion Apr 2025. No results posted. Record updated Jan 2026. |
| NCT06065540 | REIMAGINE 2: CagriSema against semaglutide, cagrilintide and placebo for blood sugar and weight in type 2 diabetes treated with metformin, with or without an SGLT2 inhibitor. | Phase 3, 2,734 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 405 sites in 32 countries and regions. Completed. Started Sep 2023; primary completion Nov 2025. No results posted. Record updated Jul 2026. |
| NCT06131372 | Whether CagriSema, against semaglutide, cagrilintide and placebo, reduces kidney damage in people with chronic kidney disease, type 2 diabetes and overweight or obesity. | Phase 2, 626 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 129 sites in 13 countries and regions. Completed. Started Apr 2024; primary completion Sep 2025. No results posted. Record updated Sep 2026. |
| NCT06323174 | REIMAGINE 1: CagriSema or placebo for blood sugar and weight in type 2 diabetes treated with diet and exercise. | Phase 3, 189 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 50 sites in 7 countries and regions. Completed. Started Mar 2024; primary completion Oct 2025. No results posted. Record updated Sep 2026. |
| NCT06221969 | CagriSema against tirzepatide for blood sugar and weight in type 2 diabetes treated with metformin, with or without an SGLT2 inhibitor. | Phase 3, 1,024 people. Randomized, open label. | Novo Nordisk A/S. 197 sites in 8 countries and regions. Completed. Started Jan 2024; primary completion Mar 2026. No results posted. Record updated Oct 2026. |
| NCT06797869 | CagriSema or placebo in people with type 2 diabetes and painful nerve damage from diabetes. | Phase 2, 142 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 55 sites in 7 countries and regions. Completed. Started Jan 2025; primary completion Jun 2026. No results posted. Record updated Sep 2026. |
| NCT05813925 | CagriSema or placebo for weight loss in people in East Asia with excess body weight. | Phase 3, 331 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 28 sites in Japan, Taiwan. Completed. Started Apr 2023; primary completion Jan 2025. No results posted. Record updated Jan 2026. |
| NCT06409130 | NNC0194-0499 (a Novo Nordisk compound), cagrilintide and semaglutide, alone or combined, on liver damage and alcohol use in alcohol-related liver disease. | Phase 2, 270 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 102 sites in 14 countries and regions. Completed. Started May 2024; primary completion Nov 2025. No results posted. Record updated Mar 2026. |
| NCT06716307 | Blood levels of cagrilintide and semaglutide after single doses of different versions of CagriSema. | Phase 1, 18 people. Randomized, open label. | Novo Nordisk A/S. 1 site, United States. Completed. Started Dec 2024; primary completion Mar 2025. No results posted. Record updated Aug 2026. |
| NCT06719011 | How NNC0174-1213, an experimental Novo Nordisk compound, works in people with overweight or obesity, against cagrilintide and placebo. | Phase 1, 178 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 2 sites, United States. Completed. Started Dec 2024; primary completion Jul 2026. No results posted. Record updated Aug 2026. |
| NCT05996848 | REDEFINE 6: CagriSema for weight loss in people in China with excess body weight, against a placebo group. | Phase 3, 300 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 37 sites, China. Completed. Started Aug 2023; primary completion Jan 2025. No results posted. Record updated Jan 2026. |
| NCT05394519 | REDEFINE 2: CagriSema or placebo for weight loss in people with type 2 diabetes and excess body weight. | Phase 3, 1,200 people. Randomized, placebo, blinded. | Novo Nordisk A/S. 179 sites in 13 countries and regions. Completed. Started Feb 2023; primary completion Jan 2025. No results posted. Record updated Jan 2026. |
| NCT07605052 | Blood levels of two versions of cagrilintide in adults with excess body weight. | Phase 1, 50 people. Randomized, open label. | Novo Nordisk A/S. 1 site, United States. Completed. Started May 2026; primary completion Aug 2026. No results posted. Record updated Sep 2026. |
| NCT06534411 | REIMAGINE 5: CagriSema against tirzepatide for blood sugar and weight in type 2 diabetes treated with metformin, an SGLT2 inhibitor or both. | Phase 3, 1,023 people. Randomized, open label. | Novo Nordisk A/S. 163 sites in 14 countries and regions. Completed. Started Nov 2024; primary completion Jun 2026. No results posted. Record updated Oct 2026. |
| NCT06131437 | CagriSema against tirzepatide for weight loss in people with obesity. | Phase 3, 809 people. Randomized, open label. | Novo Nordisk A/S. 46 sites, United States. Completed. Started Nov 2023; primary completion Dec 2025. No results posted. Record updated Feb 2026. |
Thymosin alpha-1 (thymalfasin)
Three trials in China. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06024356 | Chemoradiotherapy before surgery, with a PD-1 antibody and thymalfasin, for locally advanced rectal cancer. | No phase listed, 47 people. One group, open label. | Beijing Friendship Hospital. 1 site, China. Completed. Started Sep 2023; primary completion Apr 2026. No results posted. Record updated Jun 2026. |
| NCT06139419 | Thymosin alpha-1 added to chemoradiotherapy and immunotherapy for locally advanced non-small cell lung cancer. | Phase 2, 114 people. Randomized, open label. | Sun Yat-sen University. 1 site, China. Completed. Started Jul 2023; primary completion Jun 2026. No results posted. Record updated Aug 2026. |
| NCT05339529 | PANDA II: Thymosin alpha-1 or no added treatment after surgery for acute aortic dissection. | No drug phase, 600 people. Randomized, placebo, blinded. | Nanjing Medical University. 15 sites, China. Completed. Started Jul 2022; primary completion Mar 2025. No results posted. Record updated Sep 2026. |
Thymosin beta-4 (RGN-259)
SEER-2 is a phase 3 trial of an eye solution, not an injection. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT05555589 | SEER-2: RGN-259, a 0.1% thymosin beta-4 eye solution, or placebo for neurotrophic keratopathy. | Phase 3, 70 people. Randomized, placebo, blinded. | ReGenTree, LLC. 50 sites in 4 countries and regions. Completed. Started Apr 2023; primary completion Jul 2026. No results posted. Record updated Nov 2026. |
Cerebrolysin
One trial. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06052787 | Cerebrolysin with amantadine sulfate in people with a traumatic brain injury in intensive care. | Phase 3, 150 people. Randomized, blinded. | Ain Shams University. 1 site, Egypt. Completed. Started Sep 2023; primary completion May 2025. No results posted. Record updated Nov 2025. |
PT-141 (bremelanotide)
One small study of how much of the drug reaches breast milk. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06867835 | How much bremelanotide (Vyleesi) passes into breast milk after one dose in lactating women. | Phase 4, 10 people. One group, open label. | Cosette Pharmaceuticals, Inc.. 1 site, United States. Completed. Started Jul 2025; primary completion Nov 2025. No results posted. Record updated Jan 2026. |
Oxytocin
Added Nov 16, 2026. Seven trials outside obstetrics, from postoperative delirium and pain to benzodiazepine withdrawal and brain-wave studies in healthy people. Six more finished in labor and delivery care and are counted, not listed. We left out an observational study of saliva oxytocin and a midwifery training study. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT06945926 | Nasal oxytocin given before surgery to people aged 65 and older having orthopedic surgery under general anesthesia, to see whether it prevents delirium in the 7 days afterward. One group, no comparison. | Phase 2, 227 people. One group, open label. | Zhejiang University. 1 site, China. Completed. Started Jun 2025; primary completion May 2026. No results posted. Record updated Aug 2026. |
| NCT06881459 | GLOXY-2: Oxytocin infusion or placebo, in a crossover in men aged 18 to 70 with type 1 diabetes, to see how it changes glucagon release during low blood sugar. | No drug phase, 16 people. Randomized, placebo, blinded. | University Hospital, Gentofte, Copenhagen. 1 site, Denmark. Completed. Started Mar 2025; primary completion Jul 2025. No results posted. Record updated Sep 2025. |
| NCT06757517 | Oxytocin nasal spray (Syntocinon, 16 IU three times a day) or placebo spray during a 21-day benzodiazepine taper in adults aged 18 to 65, to see whether it reduces withdrawal symptoms. | Phase 2, 66 people. Randomized, placebo, blinded. | St. Olavs Hospital. 1 site, Norway. Completed. Started Mar 2022; primary completion Nov 2025. No results posted. Record updated Sep 2026. |
| NCT07053774 | Intravenous oxytocin (10 IU in two 30-minute infusions) and nasal oxytocin, each against a matching placebo, in a crossover in adults aged 18 to 75, to compare how well each route lowers heat pain. | Phase 2, 24 people. Randomized, placebo, blinded. | Wake Forest University Health Sciences. 1 site, United States. Completed. Started Nov 2025; primary completion Jun 2026. No results posted. Record updated Jun 2026. |
| NCT06651476 | Intravenous oxytocin (10 IU in two 30-minute infusions) or placebo, with vibration, in adults aged 18 to 55 with a mild UV-B sunburn, to see whether oxytocin raises the heat-pain threshold. | Phase 2, 38 people. Randomized, placebo, blinded. | Wake Forest University Health Sciences. 1 site, United States. Completed. Started Dec 2024; primary completion Nov 2025. No results posted. Record updated Jan 2026. |
| NCT06605300 | Nasal oxytocin (24 IU) or vasopressin (20 IU), or placebo, in healthy adults aged 18 to 30, to see how they change delta-beta brain-wave coupling at rest and during tasks on EEG. | No drug phase, 120 people. Randomized, placebo, blinded. | University of Electronic Science and Technology of China. 2 sites, China. Completed. Started Oct 2024; primary completion Jul 2025. No results posted. Record updated Oct 2025. |
| NCT04523922 | COPE+OT: Nasal oxytocin (40 IU, taken before each session) or placebo added to 12 weekly sessions of exposure therapy (COPE) in veterans with alcohol use disorder and PTSD. The main measures are alcohol use and PTSD symptom severity. | Phase 2, 175 people. Randomized, placebo, blinded. | Medical University of South Carolina. 1 site, United States. Completed. Started Mar 2021; primary completion Apr 2026. No results posted. Record updated Jul 2026. |
Triptorelin
Added Nov 16, 2026. One phase 2 window-of-opportunity trial in premenopausal breast cancer, in which triptorelin is given with the study drug or with anastrozole. We left out an observational study of quality of life and hormone levels in women taking triptorelin. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT05896566 | PREcoopERA: Giredestrant alone, giredestrant with triptorelin, or anastrozole with triptorelin, before surgery, in premenopausal women with ER-positive, HER2-negative breast cancer. The main measure is the change in Ki-67, a marker of tumor cell growth. | Phase 2, 231 people. Randomized, open label. | ETOP IBCSG Partners Foundation. 37 sites in 6 countries and regions. Completed. Started Jan 2024; primary completion Sep 2025. No results posted. Record updated Feb 2026. |
NAD+
Added Nov 16, 2026. One is a combination of NAD+ nasal spray with other drugs in older adults; the other tests three versions of an oral supplement sold as NAD+. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT07475546 | A combination of NAD+ nasal spray (30 mg a day), low-dose naltrexone, vitamin B12 and metformin, with or without added low-dose rapamycin, a glutathione skin patch and a supplement blend, against placebo, in adults aged 60 to 80 for 90 days. The main measures are VO2 max, cognitive performance and an inflammation index. | Phase 3, 26 people. Randomized, placebo, open label. | AgelessRx. 1 site, United States. Completed. Started Jul 2025; primary completion Apr 2026. No results posted. Record updated Oct 2026. |
| NCT07132801 | Three versions of an oral supplement sold as NAD+ (two capsules a day for 28 days), or placebo, in healthy adults aged 35 to 75, to see whether they raise intracellular NAD+ levels. | No drug phase, 76 people. Not randomized, blinded. | Qualia Life Sciences. 1 site, United States. Completed. Started Apr 2026; primary completion May 2026. No results posted. Record updated Oct 2026. |
Glutathione
Added Nov 16, 2026. Three of the five measure how much glutathione reaches the blood after oral products; one tests a tablet for facial dark spots and one a gel for gum pigmentation. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT07302828 | Vitamin C and glutathione liquid sachets, plain or liposomal (1,000 mg of vitamin C and 60 mg of glutathione per sachet, two sachets a dose), in a crossover, to see whether the liposomal version is absorbed better. The main measures are blood vitamin C and glutathione levels. | No drug phase, 20 people. Randomized, blinded. | TCI Co., Ltd.. 1 site, Taiwan. Completed. Started Dec 2025; primary completion Jan 2026. No results posted. Record updated Feb 2026. |
| NCT07162623 | An effervescent tablet containing glutathione, or a placebo tablet, in adults aged 21 to 55 with facial dark spots, to see whether it changes skin radiance and pigmentation (Glossymeter and Mexameter readings). | No drug phase, 62 people. Randomized, placebo, blinded. | NovoBliss Research Pvt Ltd. 1 site, India. Completed. Started Sep 2025; primary completion Apr 2026. No results posted. Record updated Aug 2026. |
| NCT06345950 | Three oral glutathione capsules compared in a crossover in healthy adults aged 21 to 65: liposomal (300 mg), standard (500 mg) and a new micellar form (300 mg). The main measures are how much glutathione reaches the blood (AUC, Cmax and Tmax). | No drug phase, 16 people. Randomized, blinded. | Factors Group of Nutritional Companies Inc.. 1 site, Canada. Completed. Started Jun 2022; primary completion Jun 2025. No results posted. Record updated Feb 2026. |
| NCT07221955 | Two versions of an oral glutathione supplement, or placebo, in healthy adults aged 45 to 75, to see whether they raise whole-blood glutathione from the start to day 20. | No drug phase, 56 people. Not randomized, blinded. | Qualia Life Sciences. 1 site, United States. Completed. Started Nov 2025; primary completion Dec 2025. No results posted. Record updated Oct 2026. |
| NCT07748507 | Microneedling of the gums with or without 0.5% glutathione gel, in a split-mouth comparison, for dark gum pigmentation. The main measures are the SEMPI pigmentation index and the pigment surface area. | No drug phase, 15 people. Randomized, blinded. | Krishnadevaraya College of Dental Sciences & Hospital. 1 site, India. Completed. Started Jun 2025; primary completion Dec 2025. No results posted. Record updated Aug 2026. |
Kisspeptin
Added Nov 15, 2026. The record calls the compound kisspeptin 112-121, which is kisspeptin-10 (UniProt, 2026). A second finished record at the same hospital, a genetics study of inherited reproductive disorders, gives no kisspeptin and is left out. What the research shows.
| Registry record | What it tests | Design | Sponsor, place and dates |
|---|---|---|---|
| NCT05633966 | KASPR: Kisspeptin (listed as kisspeptin 112-121) given under the skin in pulses about every 90 minutes for two weeks, in women aged 18 to 45 with hypothalamic amenorrhea, absent periods linked to a low hormone signal from the brain. The main measure is whether a follicle matures to 18 mm or the ovary releases an egg. One group, no comparison. | Phase 1, 13 people. One group, open label. | Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 1 site, United States. Completed. Started Dec 2022; primary completion Aug 2025. No results posted. Record updated Oct 2025. |
Oxytocin: on Nov 16, 2026 the registry listed 15 oxytocin trials that finished since January 2025 with no results posted. Seven outside obstetrics are listed above; 6 in labor and delivery care are counted here and not listed, and 2 are left out (an observational study and a training study).
Large programs, linked rather than listed
These compounds are tested in many different conditions, so one list wouldn’t help you; the registry’s search lets you filter by condition and place. The counts are records that name the compound as a treatment and are active but not recruiting on Nov 13, 2026. The registry’s own search also matches related terms, so its count can be higher than ours.
| Compound | Active trials naming it as a treatment | Of those, phase 3 | Registry search |
|---|---|---|---|
| Semaglutide | 51 | 14 | Search the registry |
| Tirzepatide | 31 | 7 | Search the registry |
| Liraglutide | 7 | 1 | Search the registry |
| Methylene blue | 3 | 0 | Search the registry |
| Triptorelin as background hormone therapy | 11 | 6 | Search the registry |
Compounds with no trial under way we found
We searched each compound on this site by name and by its other names. These had no active-not-recruiting trial, and no trial that finished since January 2025 without results, that names them as a treatment: BPC-157, TB-500, KPV, GHK-Cu, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHRP-2, GHRP-6, Hexarelin, IGF-1 LR3, IGF-1 DES, MGF, PEG-MGF, Follistatin-344, ACE-031, AOD-9604, HGH fragment 176-191, AICAR, BAM15, SLU-PP-332, 5-amino-1MQ, Tesofensine, MOTS-c, Epitalon, FOXO4-DRI, Humanin, Selank, Semax, DSIP, Dihexa, Pinealon, PE-22-28, Enclomiphene, Melanotan 2, Argireline, SNAP-8, Syn-Ake, Pentapeptide-18, Pal-GHK, Syn-Coll, Nonapeptide-1, AHK-Cu, Cartalax, Testagen, Vilon, Cardiogen, Prostamax, Bronchogen, Vesugen, Cortagen, Chonluten, Ovagen, Pancragen, Thymalin, GLOW, KLOW, ARA-290, LL-37, PNC-27, Dermorphin. NAD+ and glutathione have no active, not recruiting trial either; their finished trials are listed above, and their recruiting trials are on the recruiting page, under NAD+ and glutathione. Open trials are on the recruiting page.
How we checked each record
- We searched by name. Every compound on this site, under its other names too, such as LUM-201 for ibutamoren and thymalfasin for thymosin alpha-1.
- We opened every record. It stays only if the compound is named in a treatment group. We dropped studies that only measure it in the blood, observational studies that mention it in a list of supplements, and gene therapies.
- We checked who is behind it. The eight Hudson Biotech records we couldn’t verify are all recruiting, so they are on the recruiting page.
- We flagged old dates. A date that has passed is marked on the row.
- We counted the same way every time. Counts come from the registry on Nov 13, 2026 (added later: kisspeptin on Nov 15, 2026, NAD+, glutathione, oxytocin and triptorelin on Nov 16, 2026) and change daily.
Not listed: the registry also shows a completed 2025 study of BPC-157 gummies by a supplement company, with no results posted (NCT07752381). Found a record we got wrong? Email editors@peptideresearchstudy.com.
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
Are retatrutide trials still running?
Yes. Eli Lilly has 9 retatrutide trials listed as active, not recruiting, one more recruiting (SYNERGY-Outcomes, on the recruiting page), and 9 finished with no results posted on the registry. TRIUMPH-Outcomes, the largest at 10,000 people, has an estimated primary completion date of February 2029 (NCT06383390). See what the research shows.
What does “active, not recruiting” mean?
The study is continuing, with participants receiving a treatment or being examined, but new participants are not being recruited or enrolled (ClinicalTrials.gov, 2026).
Why does a finished trial show no results?
We can’t tell for any single trial. The registry shows no results for the 49 trials listed above as finished, though results for some have been reported elsewhere, such as the trials covered on the retatrutide and cagrilintide pages.
Can I still join an active trial?
No. By the registry’s definition, new participants are not being recruited or enrolled in an active, not recruiting trial. Trials that are open are on the recruiting page.
When will the CagriSema trials finish?
The seven active trials of cagrilintide or CagriSema have primary completion dates from October 2024 (REDEFINE 1, still listed as active) to August 2028. REDEFINE 3, which follows 7,101 people for heart attacks and strokes, is due in September 2027 (NCT05669755).
Sources
- ClinicalTrials.gov. Studies that are active, not recruiting, and studies completed since January 2025 with no results posted, for each compound on this site; API v2 query and record-by-record review, Nov 13, 2026. Registry
- ClinicalTrials.gov. Protocol Registration Data Element Definitions: Overall Recruitment Status and Primary Completion Date. ClinicalTrials.gov page
- Health Canada. Peptides: Research and clinical trials. Page dated October 23, 2026. Health Canada page
Last reviewed Nov 13, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.